#1 Clinical Trials Search in Europe

Study on the Effects of Riociguat in Patients with Pulmonary Hypertension Due to Left Heart Failure

2 1

What is this study about?

This clinical trial is focused on studying a condition known as pulmonary hypertension, which is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. Specifically, the study is looking at pulmonary hypertension that is associated with a condition called left ventricular systolic dysfunction, where the left side of the heart does not pump blood effectively. The treatment being tested in this study is a medication called Riociguat, which is taken as a film-coated tablet. Riociguat is being evaluated for its effects on the heart and blood vessels in patients with this type of pulmonary hypertension.

The purpose of the study is to assess how Riociguat affects the heart and blood flow in patients with pulmonary hypertension linked to left heart failure. Participants in the study will be randomly assigned to receive either Riociguat or a placebo. The study will be conducted over a period of time, during which participants will take the medication and undergo various tests to monitor their heart function and overall health. These tests will include measurements of blood pressure in the lungs and assessments of heart performance.

Throughout the study, the safety of Riociguat will be closely monitored, and blood samples will be collected to understand how the drug is processed in the body. The study aims to provide valuable information on the potential benefits and safety of Riociguat for patients with pulmonary hypertension associated with left ventricular systolic dysfunction. Participants will be followed up regularly to track any changes in their condition and to ensure their well-being during the trial.

1 joining the study

Upon joining the study, the participant is required to provide written informed consent, confirming understanding and willingness to participate in the trial.

Eligibility is confirmed based on criteria such as age, medical condition, and previous treatments.

2 baseline assessment

Initial assessments are conducted to establish baseline measurements. These include tests to measure heart function and blood pressure in the lungs.

A right heart catheterization (RHC) is performed to measure pressures in the heart and lungs.

3 medication administration

Participants are randomly assigned to receive either Riociguat Bayer or a placebo. The medication is administered orally in the form of a film-coated tablet.

The dosage and frequency of administration are determined by the study protocol and are monitored throughout the trial.

4 ongoing assessments

Regular assessments are conducted to monitor the participant’s health and response to the medication. These include measuring changes in heart and lung function.

Participants undergo tests such as echocardiography and blood tests to evaluate the effects of the treatment.

5 final assessment

At the end of the study period, a final assessment is conducted to evaluate the overall impact of the treatment.

The primary focus is on changes in pulmonary artery pressure and other key health indicators.

6 completion of the study

Upon completion of the study, participants may receive information about the results and any potential next steps in their treatment plan.

The study aims to conclude by the estimated end date of December 31, 2025.

Who Can Join the Study?

  • Participants must be between 18 and 80 years old at the time they agree to join the study.
  • Both men and women with symptomatic pulmonary hypertension linked to left ventricular systolic dysfunction (PH-sLVD) can join. This condition is due to ischemic heart disease or dilated cardiomyopathy (DCM). People waiting for a heart transplant can also participate. Other types of pulmonary hypertension must be ruled out.
  • PH-sLVD is defined as having a left ventricular ejection fraction (LVEF) of 40% or less, which is determined by tests like echocardiography or heart catheter exams. Also, the mean pulmonary artery pressure (PAPmean) should be 25 mmHg or higher at rest, measured by a right heart catheter (RHC).
  • Participants must have been treated with the best possible therapy for chronic heart failure (CHF) according to guidelines. This includes medications like ACE inhibitors, ARBs, beta blockers, and MR antagonists. The medication doses must have been stable for more than 30 days before joining the study. Diuretic therapy should be stable for at least 1 week before the baseline RHC.
  • RHC results for confirming PH should not be older than 1 week at the first visit. The test must be done at the participating center under standard conditions.
  • Results from a left heart catheter test should be available before joining the study to determine if the heart condition is due to ischemic heart disease or DCM.
  • A negative stress test must have been done less than 1 year before joining the study to rule out obvious or hidden heart issues. This can include tests like stress ECG, stress echocardiography, or stress scintigraphy.
  • Women can participate if they are not able to have children, which includes being postmenopausal, having had certain surgeries, or if they are of childbearing potential, they must have a negative pregnancy test and use effective birth control methods during the study.
  • Participants must be able to understand and follow instructions and be willing to participate for the entire study period.
  • Participants must provide written informed consent to join the study.

Who Cannot Join the Study?

  • Patients who do not have symptoms of pulmonary hypertension linked to left ventricular systolic dysfunction. Pulmonary hypertension is high blood pressure in the blood vessels of the lungs, and left ventricular systolic dysfunction means the left side of the heart is not pumping well.
  • Patients who are not within the specified age range for the study.
  • Patients who are not part of the specified clinical trial groups.
  • Patients who are not male or female, as both genders are included in the study.
  • Patients who are not considered part of a vulnerable population, which means groups that might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Fondazione IRCCS Policlinico San Matteo Pavia Italy
Vseobecna Fakultni Nemocnice V Praze Prague Czechia
Uslrhuiabw Haypiuhj Ckbyhgj Cologne Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Czechia Czechia
Not recruiting
14.04.2010
Germany Germany
Not recruiting
14.04.2010
Italy Italy
Not recruiting
14.04.2010

Trial locations

Investigated drugs:

Riociguat is a medication being studied for its effects on blood flow in patients with pulmonary hypertension, which is high blood pressure in the lungs, associated with left ventricular systolic dysfunction. This medication is being tested to see how it affects the heart and blood vessels, and to ensure it is safe for patients with this condition.

Pulmonary Hypertension Associated with Left Ventricular Systolic Dysfunction (PH-sLVD) – This condition occurs when there is high blood pressure in the lungs’ arteries, linked to the heart’s left ventricle not pumping effectively. The heart’s left ventricle is responsible for pumping oxygen-rich blood to the body, and when it weakens, it can lead to increased pressure in the pulmonary arteries. Over time, this increased pressure can cause the right side of the heart to work harder, potentially leading to heart enlargement and further complications. Symptoms often include shortness of breath, fatigue, and swelling in the legs and ankles. As the condition progresses, it can significantly impact a person’s ability to perform physical activities. Monitoring and managing the condition is crucial to prevent further heart strain and maintain quality of life.

Trial ID:
2023-507001-34-00
Protocol code:
14308
NCT ID:
NCT01065454
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Testing the safety of stopping riociguat in patients with chronic thromboembolic pulmonary hypertension after successful balloon pulmonary angioplasty treatment

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +4